drugset / Trial / NCT07184645
A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To investigate the superiority of 0.3% OPA-15406 foam to the vehicle in children with atopic dermatitis (AD)
Timeline
- Start
- 2025-09
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Difamilast | Small molecule | 0.3 % | Topical |
| Subject | Difamilast | Small molecule | 1 % | Topical |